KPTI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Karyopharm Therapeutics Inc (KPTI) is not a strong buy at the moment for a beginner, long-term investor. While there are some positive catalysts such as the potential upside from the Phase III SENTRY trial and improved financial management, the overbought technical indicators, insider selling, and lack of recent congress trading data or strong proprietary trading signals suggest a cautious approach. Holding the stock or waiting for further developments would be more prudent.
The technical indicators show a bullish trend with MACD positively expanding, RSI_6 at 81.491 indicating overbought conditions, and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). However, the stock is approaching resistance levels (R1: 9.439, R2: 10.392), which may limit further short-term upside.
Phase III SENTRY trial results expected in March, which could reposition Karyopharm as a key player in myelofibrosis treatment.
Improved financial management with reduced R&D and administrative expenses.
Revenue guidance for 2026 indicates potential growth.
Insiders are selling heavily, with a 599.43% increase in selling activity over the last month.
The stock is overbought based on RSI, which could lead to a near-term pullback.
No significant hedge fund activity or congress trading data to support confidence in the stock.
In Q4 2025, revenue increased by 11.58% YoY to $34.08M, and net income improved significantly (up 232.03% YoY) but remains negative at -$102.2M. EPS improved to -5.68 (up 54.77% YoY), and gross margin increased slightly to 95.65%. The company has a cash runway extending into Q2 2026.
Cantor Fitzgerald initiated coverage with an Overweight rating, citing a 70% probability of success for the Phase III SENTRY trial in myelofibrosis. A successful trial could significantly reposition the company and drive upside.
